Linking international clinical research with stateless populations to justice in global health

BMC Medical Ethics

Table 1 T-CAB members and VHX trial participants’ views on whether malaria is a health concern

Interviewee	Identifies malaria as a health concern*	Reason(s)
T-CAB Member 01	No.	Has gained knowledge on how to prevent malaria.
T-CAB Member 02	Yes.	If gets malaria, cannot work. If gets cerebral malaria, can die.
T-CAB Member 03	Yes. Thinks people in his village worry as well.	If gets malaria, cannot work. “I cannot eat foods, I will not be able to do any kind of social activities and family matter and then it can effect to all of our business sector, social sector, and education sector.” If severe, malaria virus can cause death.
T-CAB Member 04	Yes. Thinks people in her village worry as well.	Large (falciparum) and small (vivax) malaria virus can cause death.
Trial Participant 01	Yes. And worries about malaria repeating again.	If unhealthy, cannot work.
Trial Participant 02	Yes.	Has seen people die from malaria.
Trial Participant 03	Yes, worries most about malaria virus.	Scared of “losing my physical body”.
Trial Participant 04	Yes, worries most about malaria virus.	Can die if don’t receive treatment.
Trial Participant 05	Yes, worries for cerebral malaria.	Can put life in danger.
Trial Participant 06	Yes.	Scared of dying, forgetting things, going crazy, becoming unconscious.
Trial Participant 07	Yes, worries for cerebral malaria.	If virus goes to brain, can die.
Trial Participant 08	Yes, worries for cerebral malaria.	Die if virus goes to the brain.

*Note: T-CAB members are specifically referring to vivax when they say they are worried about malaria, as they were asked “Do you worry about getting vivax malaria?”. However, trial participants were asked “Do you worry about getting malaria?” because they were unlikely to know that there are different types of malaria. As a result, their answers may refer to falciparum or vivax. Where trial participants mention cerebral malaria or its symptoms (e.g., trial participants 05–08), they are expressing a concern for falciparum. Trial participants 02–04 may also be referring to falciparum rather than vivax because falciparum is more commonly associated with death than vivax. Of the trial participants interviewed, trial participant 01 is the most likely to be identifying vivax as a concern, as he mentions relapsing.

ISSN: 1472-6939